This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone Sep 2026 quarter: revenue up 30.4%, profit after tax up 15.0% despite exceptional items
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone quarter ended September 30, 2026: revenue was Rs 729.1 crore, up 30.4% from Rs 559.1 crore a year ago; profit after tax was Rs 62.3 crore, up 15.0% from Rs 54.2 crore. Exceptional items were Rs 15.0 crore, with Rs 15.6 crore land-charge interest. Standalone half-year revenue rose 30.1% to Rs 1,411.9 crore, while profit after tax fell 9.0% to Rs 100.2 crore. NPPA's Rs 148.7 crore demand has no provision; court has stayed collection.
Revenue growth supports the stock, but the exceptional charge and NPPA demand may weigh on sentiment; half-year profit was lower year on year.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹729.1 Cr | ₹559.1 Cr | +30.4% |
| Operating profit | ₹88.33 Cr | ₹71.94 Cr | +22.8% |
| Profit after tax | ₹62.33 Cr | ₹54.22 Cr | +15.0% |
| EBITDA margin | 11.1% | 12.5% | −1.4 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.